ProKidney (PROK) Earnings Date & Reports

Key Takeaways

• ProKidney Corp. (PROK) is expected to report third-quarter 2026 results around November 9–10, 2026, with a conference call scheduled for November 10 at 4:00 p.m. ET.
• Wall Street consensus points to a net loss of roughly $0.13 to $0.14 per share, alongside minimal revenue of approximately $0.12 million to $0.15 million.
• As a late clinical-stage cell therapy company, ProKidney remains essentially pre-revenue, so investors will focus on cash burn, research and development (R&D) spending, and clinical updates rather than top-line growth.
• The company recently completed enrollment for the Phase 3 PROACT 1 accelerated approval efficacy analysis, with pivotal eGFR (estimated glomerular filtration rate) slope topline results anticipated in Q2 2027.
• ProKidney's cash position of roughly $225 million is expected to fund operations into mid-2027, making capital-efficiency commentary a key watch item.
• For additional detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated ProKidney pages.
• Investors seeking broader market ideas can explore Trending AI Robots for additional trading insights.

Earnings Context and Why It Matters

ProKidney is advancing rilparencel (REACT), an autologous cell therapy for advanced chronic kidney disease (CKD) in patients with type 2 diabetes. Because the company generates almost no product revenue, its quarterly reports serve primarily as a gauge of clinical execution and financial runway. Prior quarters have shown disciplined spending, with R&D and general and administrative expenses trending lower year over year. The upcoming report arrives just months after the company completed enrollment for its Phase 3 PROACT 1 accelerated approval analysis and secured U.S. Food and Drug Administration (FDA) alignment on eGFR slope as a surrogate endpoint. For investors, the update offers a timely read on trial progress, expense control, and how long existing cash can sustain operations ahead of a pivotal data readout.

Earnings Expectations

Analysts expect ProKidney to report a net loss of approximately $0.13 to $0.14 per share for the third quarter of 2026, with consensus revenue of roughly $0.12 million to $0.15 million. A year earlier, in the third quarter of 2025, the company posted a net loss of $0.12 per share on revenue of about $0.22 million, reflecting the minimal, non-recurring nature of its revenue base.

More recent history shows mixed results against estimates. In the second quarter of 2026, ProKidney reported a loss of $0.15 per share, slightly missing the $0.14 consensus, while revenue of $0.15 million also came in below expectations. Given the company's pre-revenue profile, analysts and investors will weigh operating losses and cash consumption more heavily than the top line. Key metrics to watch include net loss before noncontrolling interest, R&D expense, and the cash, cash equivalents, and marketable securities balance at quarter end.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener supports the identification of trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for building watchlists around events such as the ProKidney earnings release.

Market Reaction and Investor Sentiment

Sentiment heading into the report is shaped less by earnings estimates than by the clinical timeline. ProKidney's shares have traded well below their 52-week high as investors weigh the long gap until pivotal PROACT 1 data in Q2 2027 and the need to preserve capital. The recent completion of enrollment for the accelerated approval efficacy analysis was viewed as a positive de-risking step, though the stock has historically reacted modestly around earnings. Key risk factors include any signals of slower trial progress, higher-than-expected cash burn, or changes to the anticipated mid-2027 runway. Conversely, any incremental regulatory or enrollment clarity could support sentiment.

Forward Outlook and Key Factors to Monitor

Following the third-quarter report, investors should watch several forward-looking themes. First is cash runway: ProKidney has guided that existing cash should fund operations into mid-2027, so any revision to that timeline would carry significant weight.

Second is execution on PROACT 1, the Phase 3 REGEN-006 study. With enrollment for the accelerated approval efficacy analysis complete, attention turns to whether the company remains on track for pivotal eGFR slope topline results in the second quarter of 2027. Management commentary on data-readout timing and any interim interactions with the FDA will be closely parsed.

Third is expense discipline. Recent quarters have shown lower R&D spending as earlier studies wind down, and investors will look for confirmation that this trend continues without compromising the registrational program. Finally, any updates on manufacturing readiness, RMAT (Regenerative Medicine Advanced Therapy) designation progress, or potential partnerships could shape the outlook.

As a pre-revenue biotech, ProKidney's near-term story hinges on clinical milestones and balance-sheet management rather than traditional earnings growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations